Smart Thalassaemia Diagnostic System
IoT-enabled Testing Device AI-enabled Decision Suppport
IoT-enabled Testing Device AI-enabled Decision Suppport
In south-East-Asian countries. Pakistan is one of the few with highest prevalence.
USD 203 Million approx. direct & indirect treatment cost per year per 100k patients (Pak).
β-Thalassemia results in approx. 50,000–100,000 deaths annually around the globe.
Thalassaemia is an inherited blood-related disorder in which one or more globin chains are either not produced at all or are produced at a reduced rate.
For a couple, if one of the partners carry the abnormal thalassaemia gene, there's a 50% risk of giving birth to 'Thalassaemia Minor' children.
For a couple, if both of the partners carry the abnormal thalassaemia gene, there's a 50% risk of giving birth to 'Thalassaemia Minor' children and 25% risk of giving birth to 'Thalassaemia Major' children.
In Pakistan, Punjab thalassaemia prevention program is active but the initiative hasn’t met the desired outcome. The screening devices are expensive, high maintenance and require expert handling. Diagnosis is expert-intensive and reports are often delayed with patients travelling from far areas to get tested.
ThalaScreen is carrying out cutting-edge research in collaboration with expert haematologists to diagnose for Thalassaemia with advanced AI-algorithms. Our research objective is to prevent the spread of this national-level disease through an innovative digital thalassaemia diagnostic system.
Muhammad Salman Khan, Azmat ullah, Kaleem Nawaz Khan, Huma Riaz, Yasar Mehmood, Tawsifur Rehman, Muhmmad E.H. Chowdhury, “Automated Assessment of Thalassaemia from Haemoglobin Electrophoresis Images using Convolutional Neural Network”.
Patent filing in process, “Device, method and system for haemoglobin electrophoresis, automated image analysis and internet-of-things-enabled telepathology”.
Our research collaborators include Khyber Medical College & University, Lady Reading Hospital, Hayatabad Medical Complex, KP Health Department, Rehman Medical Institute, Peshawar, Pakistan.
ThalaScreen's team comprises of AI experts, biomedical, electronics and cloud engineers, software developers and haematologists.
ThalaScreen got incubated in National Incubation Center, Peshawar in September of 2019 as a health-tech innovator after successful pitching sessions. During its period of incubation, the team has been able to understand multiple aspects of market research and business development.
ThalaScreen was selected among only 20 startups from entire Pakistan for training under U.S Department of State’s Global Innovation through Science and Technology (GIST) Initiative. This bootcamp-styled training was very insightful in terms of refining our customer segments, customer channels and value propositions
ThalaScreen is soon going to revolutionize the testing of thalassaemia helping thousands of patients particularly from far flung areas. ThalaScreen aims to develop a central database as a national repository for Thalassaemia minor population to facilitate targeted screening.
For any type of queries and/or pre-order requests, please contact with the information provided.
thalascreen@gmail.com
+92 316 9595140